Litigation Risks Associated with AI in Healthcare

27 Jun , 2022

To register for the upcoming live webinar, please Click Here

With spending on the use of Artificial Intelligence (AI) in healthcare anticipated to skyrocket in the next two years, healthcare professionals, counsel and claims professionals need to prepare themselves now for the medicolegal issues that are coming. 

This lecture will focus on how AI is being used in medicine and its anticipated negative consequences, including new medical professional liability risks and discovery issues. The program is designed to educate, inform and enlighten those in healthcare risk management, claims management and information technology about the next revolution in healthcare: the use of AI in medical decision-making.

 

To register for the upcoming live webinar, please Click Here

More Webcasts

Litigation Series: T...

The “Chaptering Your Cross” program explains how dividing a cross?examination into clear...

Building Inclusive L...

This interactive course is designed to equip legal professionals with the knowledge, tools, and stra...

Who is Your Lawyer o...

Recent court opinions, a lawsuit against OpenAI Foundation and OpenAI Group PBC aka ChatGPT for the ...

Freediving Through F...

Most legal professionals are operating in survival mode whether they realize it or not. Not crisis-l...

Litigation Series: E...

Part 1 - This program focuses specifically on cross?examining expert witnesses, whose credentials an...

Complying with the M...

This course will provide a detailed overview of the Medicare Secondary Payer act as well as provide ...

National Security & ...

In an era of heightening geopolitical tension, the protection of sensitive personal data has moved f...

Ethics, Confidential...

Artificial intelligence is already reshaping legal practice, from research and drafting to litigatio...

Oral Advocacy: Winn...

For most new attorneys, learning how to frame an oral argument can be a daunting task.   L...

Appreciating 340B Dr...

Established in 1992, the 340B Drug Pricing Program has many nuances and applications to different si...